ACAD · NASDAQ
ACADIA Pharmaceuticals Inc.
$20.17 +0.43 (+2.18%)
Company overview
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. Its pipeline includes pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis and negative symptoms of schizophrenia; trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $3.5B
- Employees
- 653
- Headquarters
- San Diego, CA
- Website
- acadia-pharm.com
- CEO
- Catherine E. Owen Adams
- Listed
- May 27, 2004
- P/E
- 9.04
- Dividend yield
- 0.00%
Company financials
- Revenue
- $1.1B
- Gross profit
- $1B
- Operating income
- $80.9M
- EBITDA
- $105M
- Net income
- $376M
- EPS
- $2.23
- Total assets
- $1.6B
- Total debt
- $50.8M
- Gross margin
- 91.47%
- Net margin
- 34.30%
- Earnings yield
- 11.06%
ACAD
1D
NASDAQ
O19.72H19.89L19.59C19.74+0.01 (+0.05%)Vol1.23M